Ilaris (canakinumab) — Highmark
Hyperimmunoglobulin D Syndrome (HIDS)
Initial criteria
- age ≥ 28 days
- diagnosis of TRAPS OR HIDS OR MKD OR FMF
- prescribed by or in consultation with a rheumatologist, nephrologist, geneticist, gastroenterologist, oncologist, or hematologist
Reauthorization criteria
- member is tolerating therapy AND has experienced disease improvement OR delayed disease progression